Susceptibility of diabetic heart to catecholamine-induced arrhythmias is independent of contractile dysfunction
Abstract
Background: Diabetes is associated with myocardial electrical instability and prolongation of action potential duration that result in disturbances in the rhythm of the heart.
Objective: This study was undertaken to examine the role of circulating catecholamines in abnormal cardiac rhythm and contractility during different stages of diabetes.
Methods: Diabetes was induced in male Sprague-Dawley rats with streptozotocin (STZ; 65 mg/kg, i.v.). Epinephrine (4-128 μg/kg, i.v.) -induced arrhythmias and plasma levels of epinephrine (Epi) and norepinephrine (NE) were determined in control, 4- and 8-wk diabetic animals. Echocardiography was used to assess cardiac remodeling and contractile function.
Results: Although diabetes induced cardiac dysfunction, there were no significant differences in cardiac output, ejection fraction, left ventricle (LV) dimensions, LV fractional shortening between the 4- and 8-wk diabetic animals. The electrocardiogram of both diabetic groups showed deep S wave as well as changes in T wave and ST segment. In addition, prolongation of the RR interval in the 4- and 8-wk diabetic animals was seen, while prolongation of the QT and PR intervals were only seen in the 8-wk diabetic animals. The severity of Epi-induced ventricular arrhythmias, as assessed by arrhythmia score, was significantly lower in the 8-wk diabetic rats, as compared to the 4-wk diabetic animals. Circulating Epi levels were significantly decreased in the 8-wk diabetic rats, whereas NE levels were increased in the 4-wk diabetic rats.
Conclusions: The sensitivity of the diabetic heart to catecholamine-triggered arrhythmias may be dependent on circulating Epi rather than NE and thus it can be proposed that the increased incidence of sudden cardiac death in diabetics may not be associated with response to catecholamines.
References
Dhalla NS, Adameova A, Kaur M. Role of catecholamine oxidation in sudden cardiac death. Fund Clin Pharmacol 2010; 24: 539-46.
Sethi R, Rehsia NS, Jindal K, et al. Antiarrhythmic effects of some antioxidant vitamins in rats injected with epinephrine. Cardiovasc Toxicol 2009 9: 177-84.
Sethi R, Adameova A, Dhalla KS, et al. Modification of epinephrine-induced arrhythmias by N-acetyl-L-cysteine and vitamin E. J Cardiovasc Pharmacol Ther 2009; 14:134-42.
Adameova A, Abdellatif Y, Dhalla NS. Role of the excessive amounts of circulating catecholamines and glucocorticoids in stress-induced heart disease. Can J Physiol Pharmacol 2009; 8: 493-514.
Goyal BR, Mesariya P, Goyal RK, Mehta AA. Effect of telmisartan on cardiovascular complications associated with streptozotocin diabetic rats. Mol Cell Biochem 2008: 314: 123-31.
Malone MA, Schocken DD, Hanna SK, Liang X, Malone JI. Diabetes-induced bradycardia is an intrinsic metabolic defect reversed by carnitine. Metabolism 2007; 56: 1118-23.
Nobe S, Aomine M, Arita M, Ito S, Takaki R. Chronic diabetes mellitus prolongs action potential duration of rat ventricular muscles: circumstantial evidence for impaired Ca2+ channel. Cardiovasc Res 1990; 24: 381-9.
Casis O, Gallego M, Iriarte M, Sanchez-Chapula A. Effects of diabetic cardiomyopathy on regional electrophysiologic characteristics of rat ventricle. Diabetologia 2000; 43: 101-9.
Shimoni Y, Chen K, Emmett T, Kargacin G. Aldosterone and the autocrine modulation of potassium currents and oxidative stress in the diabetic rat heart. Br J Pharmacol 2008; 154: 675-87.
Jourdon P, Feuvray D. Calcium and potassium currents in ventricular myocytes isolated from diabetic rats. J Physiol 1993; 470: 411-29.
Fein FS. Diabetic cardiomyopathy. Diabetes Care 1990; 13: 1169-79.
Regan TJ, Ahmed S, Haidar B, Moschos C, Weisse A. Diabetic cardiomyopathy: Experimental and clinical observations. New Engl J Med 1994; 91: 776-8.
Ganguly PK, Pierce GN, Dhalla KS, Dhalla NS. Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am J Physiol 1983; 244: E528-35.
Rees SA, Curtis MJ. Specific IK1 blockade: a new antiarrhythmic mechanism? Effect of RP58866 on ventricular arrhythmias in rat, rabbit, and primate. Circulation 1993; 87: 1979-1789.
Barta J, Sanganalmath SK, Kumamoto H, Takeda N, Édes I, Dhalla NS. Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality. Cardiovasc Toxicol 2008; 8: 127-35.
Walker MJ, Curtis MJ, Hearse DJ, et al. The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction and reperfusion. Cardiovasc Res 1988; 22: 447-55.
Sanganalmath SK, Babick AP, Barta J, Kumamoto H, Takeda N, Dhalla NS. Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure. J Cell Mol Med 2008; 12: 1728-38.
Vasanji Z, Dhalla NS, Netticadan T. Increased inhibition of SERCA2 by phospholamban in the type I diabetic heart. Mol Cell Biochem 2004; 261: 245-9.
Machackova J, Liu X, Lukas A, Dhalla NS. Renin-angiotensin blockade attenuates cardiac myofibrillar remodelling in chronic diabetes. Mol Cell Biochem 2004; 261: 271-8.
Tappia PS, Asemu G, Aroutiounova N, Dhalla NS. Defective sarcolemmal phospholipase C signaling in diabetic cardiomyopathy. Mol Cell Biochem 2004; 261: 193-9.
Sauviat MP, Feuvray D. Electrophysiological analysis of the sensitivity to calcium in ventricular muscle from alloxan diabetic rats. Basic Res Cardiol 1986; 81: 489-96.
Howarth FC, Jacobson M, Shafiullah M, Adeghate E. Long-term effects of streptozotocin- induced diabetes on the electrocardiogram, physical activity and body temperature in rats. Physiology 2005; 90: 827-35.
Rana BS, Band MM, Ogston S, Morris AD, Pringle SD, Struthers AD. Relation of QT interval dispersion to the number of different cardiac abnormalities in diabetes mellitus. Am J Cardiol 2002; 90: 483-7.
Takebayashi K, Sugita R, Tayama K, Aso Y, Takemura Y, Inukai T. The connection between QT dispersion and autonomic neuropathy in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 2003; 111: 351-7.
Dhalla NS, Liu X, Panagia V, Takeda N. Subcellular remodeling and heart dysfunction in chronic diabetes. Cardiovasc Res 1998; 40: 239-47.
Dhalla NS, Takeda N, Rodriquez-Leyva D, Elimban V. Mechanisms of subcellular remodeling in heart failure due to diabetes. Heart Fail Rev 2014; 19: 87-99.
Marfella R, Rossi F, Giugliano D. Hyperglycemia and QT interval: time for re-evaluation. Diabetes Nutr Metab 2011; 14: 63-5.
Christensen NJ. Plasma catecholamines in long-term diabetics with and without neuropathy and in hypophysectomized subjects. J Clin Invest 1972; 51: 779-87.
Porojan M, Costin M, Poantă L, et al. Autonomic neuropathy and plasma catecholamine in patients with diabetes mellitus. Rom J Intern Med 2010; 48: 341-5.
Heyman E, Delamarche P, Berthon P, et al. Alteration in sympathoadrenergic activity at rest and during intense exercise despite normal aerobic fitness in late pubertal adolescent girls with type 1 diabetes. Diabetes Metab 2007; 33: 422-9.
Kondo K, Matsubara T, Nakamura J, Hotta N. Characteristic patterns of circadian variation in plasma catecholamine levels, blood pressure and heart rate variability in Type 2 diabetic patients. Diabet Med 2002; 19: 359-65.
Tosaki A, Engelman DT, Engelman RM, Das DK. The evolution of diabetic response to ischemia/reperfusion and preconditioning in isolated working rat hearts. Cardiovasc Res 1996; 31: 526-36.
Feuvray D, Lopaschuk GD. Controversies on the sensitivity of the diabetic heart to ischemic injury: the sensitivity of the diabetic heart to ischemic injury is decreased. Cardiovasc Res 1997; 34: 113-20.
Adameová A, Kuzelová M, Andelová E, et al. Hypercholesterolemia abrogates an increased resistance of diabetic rat hearts to ischemia-reperfusion injury. Mol Cell Biochem 2007; 295: 129-36.
Ravingerová T, Adameová A, Matejíková J, et al. Subcellular mechanisms of adaptation in the diabetic myocardium: Relevance to ischemic preconditioning in the nondiseased heart. Exp Clin Cardiol 2010; 15: 68-76.
Erickson JR, Pereira L, Wang L, et al. Diabetic hyperglycemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature 2013; 502: 372-6.
Netticadan T, Temsah RM, Kent A, Elimban V, Dhalla NS. Depressed levels of Ca2+-cycling proteins may underlie sarcoplasmic reticulum dysfunction in the diabetic heart. Diabetes 2001; 50: 2133-8.
Vasanji Z, Cantor EJ, Juric D, Moyen M, Netticadan T. Alterations in cardiac contractile performance and sarcoplasmic reticulum function in sucrose-fed rats is associated with insulin resistance. Am J Physiol Cell Physiol 2006; 291: C772-80.
Anderson ME, Brown JH, Bers DM. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol 2011; 51:468-73.
Netticadan T, Temsah RM, Kawabata K, Dhalla NS. Sarcoplasmic reticulum Ca2+/Calmodulin-dependent protein kinase is altered in heart failure. Circ Res 2000; 86: 596-605
Bhagat BD, Rao PS, Dhalla NS. Role of catecholamines in the genesis of arrhythmias. Adv Myocardial 1980; 2: 117-32.
Xu YJ, Tappia PS, Neki NS, Dhalla NS. Prevention of diabetes-induced cardiovascular complications upon treatment with antioxidants. Heart Fail Rev 2014; 19:113-21.
Dinçer UD, Bidasee KR, Güner S, Tay A, Özçelikay T, Altan MV. The effect of diabetes on expression of β1-, β2-, and β3-adrenoreceptors in rats hearts. Diabetes 2001; 50: 455-61.
Op den Buijs J, Miklos Z, Van Riel NAW, et al. β-adrenergic activation reveals impaired cardiac calcium handling at early stage of diabetes. Life Sci 2005; 76: 1083-98.
Woodcock EA, Arthur JF, Matkovich SJ. Inositiol 1,4,5-trisphosphate and reperfusion arrhythmias. Clin Exp Pharmacol Physiol 2000; 27:734-7.
Tanaka Y, Kashiwagi A, Saeki Y, Shigeta Y. Abnormalities in cardiac α1-adrenoceptor and its signal transduction in streptozotocin-induced diabetic rats. Am J Physiol 1992; 263: E425-9.
Tanaka Y, Kashiwagi A, Saeki Y, et al. Effects of verapamil on the cardiac α1-adrenoceptor signaling system in diabetic rats. Eur J Pharmacol 1993; 244: 105-9.
Ziegelhöffer A, Bundgaard H, Ravingerová, et al. Diabetes – and semi-starvation-induced changes in metabolism and regulation of Na, K-ATPase in rat heart. Diabetes Nutr Metab 2003; 16: 222-31.